Laboratory evaluation of commercial interferon preparations by Schoub, B.D. et al.
SA MEOIESE TYOSKRIF OEEL 63 8 JANUARIE 1983 33
Laboratory evaluation of commercial
interferon preparations
B. D. SCHOUB, S. F. LYONS, M. CRESPI, M.-N. CHIU, R. LOMNITZER
Summary
The antiviral, antiproliferative and natural killer-cell
(NKC) stimulatory activities of four commercial the-
rapeutic interferon preparations were assayed in
our laboratory. The antiviral and antiproliferative
activities of each preparation were relatively similar,
but an unexpectedly high NKC stimulatory activity
was foupd in one ofthem. In-house determination of
antiviral activity and evaluation of the antiprolifera'-
tive and NKC stimulation potential of-"interferon
preparations are. essential before rational clinical
trials of this agent are carried out.
S Air Med J 1983; 63: 33-38.
The exact therapeutic roie of the interferons remains to be
established and defined. Preliminary clinical trials of exoge-
nously administered interferons have shown that they have
undoubted therapeutic value in the treatment ofa variety of viral
infections, and it is probable that they may well play some
significant role in the treatment of certain forms of canceL l
The interferons are a group of proteins which have potent and
varied biological activity, including a broad-spectrum antiviral
efficacy.2-4 There are three types of interferons: H uIFN-0' (pre-
viously called leucocyte interferon), HuIFN-R (previously called
fibroblast interferon), and HuIFN""y (previously called
immune interferon). The first two types are produced by most
cells in the body in response to viral infection or exposure to
foreign polynucleotides. The third type, HuIFN""y, is pro-
duced by sensitized Iymphocytes in response to specific anti-
genic or mitogenic stimulation. These three types of interferons
may be distinguished from each other by their physicochemical,
biological, pharmacological and immunological properties,
although they share most, if not all, of their biological effects to a
greater or lesser degree. Of these biological effects the three that
are of greatest importance are: (i) the broad-spectrum antiviral
activity; (ii) inhibition of cell proliferation; and (iii) stimulation
of natural killer-cells (NKCs). Because of technical problems in
the production and purification of HuIFN-)l, this substance is
as yet unavailable in sufficient amounts for evaluation and clini-
cal trials. The clinical evaluation of the interferons has therefore
centred mainly on three products: HuIFN-O', processed from
buffy coats of donated blood units; HuIFN-R, produced from
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fibroblast cell cultures; and Iymphoblastoid interferon, derived
from a line of continuously growing Iymphoblastoid cells trans-
formed by Epstein-Barr virus, the so-called Namalwa cells. The
latter product consists of a mixture containing predominantly
HuIFN-O' with a smaller volume of HuIFN-R.;
Samples of the three types of interferon products were
obtained from commercial sources for laboratory evaluation of
their three major biological effects. The potency of the prepara-
tion is usually specified with reference to its antivirial activity,
and is· expressed in international units. A unit of interferon is
defined as that amount which produces a 50% inhibition of
replication of a test virus, measured either by inhibition of
plaque formation or infectivity in tissue culture. For this purpose
international standards are provided for the calibration of in-
house laboratory standards.6 A microtitre radio-immunoassay
technique has been developed in our laboratory to assay antiviral
activity.' This was shown to correlate with the plaque reduction
assay, while at the same time having the advantages of being very
much less cumbersome and utilizing smaller amounts of rea-
gents. The subjectivity inherent in standard antiviral assays is
thus avoided. This technique was used to quantitate the antiviral
potency of the commercial preparations of interferons in terms of
international unitage. International standards have not as yet
been established for anti proliferative and NKC stimulatory
activities; these were assayed by conventional techniques and the
results obtained for the commercial preparations compared with
our in-house laboratory standard.
Materials and methods
Sources of interferon
The following four interferon preparations were kindly pro-
vided to us for laboratory evaluation:
Frone (Inter-Veda Ltd, Rehovot, Israel). This is a preparation
of HuIFN-R produced by stimulation of human foreskin fibro-
blast cell cultures with a synthetic polyribonucleotide (poly I:C)
and superinduced with cycloheximide and actinomycin. This
preparation has a stated value of I x 106 I U/ml on reconstitution
as directed.
Namalvin (Heriff ApS; Omme, Denmark) -Iymphoblastoid
interferon prepared by stimulation of Namalwa cells with Sendai
virus. The stated potency was 4 x 106 ID/m!.
HuIFN-O' (Israel Institute for Biological Research: Ness-
Ziona, Israel) (IIBR) - this preparation is derived from buffy
coats of donor blood by stimulation of the mononuclear cells
with Sendai virus. The potency was given as 3 x 106 ID/m!.
Lymphoblastoid interferon (IIBR) - a further prepara-
tion of Iymphoblastoid interferon also produced by stimulation
of Namalwa cells with Sendai virus and with a given potency of2
x IQ6 ID/m!.
International human leucocyte standard
G023-901-527
This was obtained from the Research Resources Branch of the
National Institute of Allergy and Infectious Diseases, Bethesda,
Md, USA, and had a unitage of 20000 IU/m!.
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In-house standard
An in-house standard of Iymphoblastoid interferon was pre-
pared from Namalwa cells kindly donated by Professor M. Revel
of the Weizmann Institute of Science, Rehovot, Israel. The
cells were grown in roller bottles in RPMI 1640 supplemented
with 2% fetal calf serum (FCS). Asuspension of the cells at 0,5 x
10b/ml was distributed in 100 ml amounts into flasks of75 cm2
and N-butyric acid was added to a final concentration of I mM.
After incubation at 37°C for 48 hours the suspensions were
centrifuged and resuspended to a concentration of 2 x 10b/ml
with fresh RPMI 1640 with 2% FCS. The E82 strain of Sendai
virus, used for large-scale production of buffy-coat HuIFN-a,
was obtained from Dr K. Cantell of the Central Public Health
Laboratory at Helsinki, and was grown in the allantoic cavity of
embryonated chick eggs. The inducer virus was added to the
Namalwa cells at a titre of 100 haemagglutinating units per lOb
viable cells, and the suspensions incubated overnight at 35°C.
The cells were then pelleted and the supernatant used as crude
Namalwa interferon. The in-house standard was calibrated
against the international standard and its unitage was calculated
at 16000 IU/ml.
Mock interferon
This was prepared as for the in-house standard, but the
inducer virus was omitted. The mock interferon preparation is
not devoid of all antiviral activity, as Namalwa cells have been
shown to produce low basal levels of interferon even in the
absence of any inducing condition.8
Antiviral radio-immunoassay
This technique has been described in greater detail else-
where. 7 The test is based on the quantitation by radio-immuno-
assay of the reduction of growth of challenge Sindbis virus due to
the protection of cells by the interferon samples.
Briefly, confluent monolayers of Vero cells were grown in
microtitre plates and dilutions ofthe relevant interferon prepara-
tions in Eagle's minimum essential medium with 2% FCS were
added. Initially, seriallO-fold dilutions ranging from 10-1 to 10-4
were tested, followed by 2-fold dilutions for finer adjustment.
After an incubation period of 18 - 24 hours at 37° C in a 5%
CO2/air mixture, the medium was removed and the cells washed
twice. The cells were then challenged with a dilution of Sindbis
virus, usually I: 1000, previously calculated to produce optimal
sensitivity for the detection of interferon. After further overnight
incubation the medium was removed, the monolayer washed 3
times and fixed with methanol at - 20°C for 2 hours. The
methanol was removed and the plates air-dried. The cells were
then washed 3 times and 50 I..Ll of murine anti-Sindbis ascitic
fl uid was added at a predetermined optimal titre, usually 1: 100.
The cells were then incubated for 1hour at 37° C, washed 3 times
and 100 I..Ll of 125I-protein A (Radiochemical Centre Ltd; Amer-
sham, UK) at 300 cpm!I.Ll was added to each well. After further
incubation at 37°C for I hour the cells were washed 4 times and
solubilized by adding 100 J.LI of a mixture of O,IN NaOH and
0,1% sodium dodecyl sulphate. Aliquots of 50 J.LI were trans-
ferred to tubes for counting in a gamma counter.
The endpoint was determined as the highest dilution of inter-
feron giving a 50% reduction of counts, and the unitage calcu-
la ted by relating this titre to that obtained for the international or
the in-house standard.
Antiproliferative assay
Human amnion cells, which are in the routine diagnostic
laboratory for the isolation of viruses, were employed to deter-
mine the antiproliferative activities of the various interferon
preparations. The cells were seeded at 1,5 x 105/ml in 24-well
tissue culture plates (Linbro, Flow Laboratories). The interferon
preparations were incorporated into the medium at the same
dilutions as for the antiviral assay and the cells were then incu-
bated for 72 hours at 37°C in a 5% CO2/air mixture. Mitotic
activity was then measured by pulsing with 3H-thymidine at 2
J.LCi/ml in minimum essential medium with 10% FCS for 1hour.
The cells were then washed with phosphate-buffered saline, pH
7,4, and 5% trichloro-acetic acid (TCA) was added for 30 minutes
at 37°C. After 2 further washings with 5% TCA a mixture of 0, IN
NaOH and 0,1 % sodium dodecyl sulphate was added and the
cells incubated at 37° C for I hour. The samples were neutralized
with IM hydrochloric acid and then counted in a scintillation
counter. The percentage inhibition of TCA precipitable counts
was recorded at specific dilutions of the various interferon
preparations.
NKC stimulation assay
Mononuclear cells, obtained by Ficoll-Hypaque density gra-
dient fractionation of peripheral blood donated by healthy
volunteers, were used as the effector cells for the KC assay.
These cells were washed 3 times in RPMI 1640 and resuspended
to a concentration of 107/ ml in the same medium. For the assay
0,8 ml of mononuclear cells (107/ml) were treated with 0,2 ml of
the interferon preparations or mock interferon and incubated for
3 hours at 37°C. The cells were then washed 3 times and resus-
pended in RPMI 1640 with 10% FCS and were then used in the
NKC assay.
The target cells used were from the myeloid line (K562),
which was maintained as a suspension culture in RPMI 1640
with 10% FCS. These cells were labelled with 5lCr by suspend-
ing approximately 3 x lOb cells in 0,2 ml medium containing 100
J.LCi of Na2 5ICr-04 and incubating for 2 hours at 37°C with-
occasional agitation. They were then washed 3 times and resus-
pended in RPMI 1640 with 10% FCS.
The NKC was performed by adding 100 J.Ll aliquots of 2 x 104
labelled target cells to each well of flat-bottomed microtitre
plates. The effector mononuclear cells were likewise added in
100 J.Ll aliquots to the plates to give an effector cell: target cell
ratio of 80: 1,40: 1,20: 1 and 10: 1 respectively. The cultures were
incubated at 37° C in 5% CO2/air for 16 hours, after which 100 J.LI
of the supernatants were removed from each well and the 51 Cr
released was quantitated in a Packard 5320 gamma counter. The
tests were all carried out three times. The percentage ofcytotox-
ity was calculated as:
experimental 51 Cr release - spontaneous 5lCr release. x 100.
total 51Cr counts - spontaneous 51Cr release
Results
Antiviral activity of interferon preparations
(Table I)
The results of the antiviral assays carried out on the interferon
preparations are given in Table I. For two preparations (the
IIBR HuIFN-a and Iymphoblastoid interferon) the values
obtained by us corresponded with those given by the manufac-
turers. With the two other commercial preparations (Frone
HuIFN -B and Namalvin Iymphoblastoid interferon) the labora-
tory-determined values were just under one-half of those given
by the manufacturers.
Antiproliferative activity of interferon prepa-
rations (Table II)
The antiprolifertive activities ofeach of the commercial prepa-
rations were determined at varying dilutions in parallel with the
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A;::: Frone; B::=: Namalvin: C = IIBR HuIFN-o: 0 = IIBR Iymphoblastoid interferon:
HS = in-house standard: IS = National Institutes of Health internationaJ standard
























. NKC activity expressed as ratio of: % SIC, released by Interferon-treated mononuclear cells.
% SI er released by untreated mononuclear cells
A = Frone: B = Namalvin: C = IIBR HuIFN-a: 0 = IIBR Iymphoblastold interferon. HS =
in-house standard: M = mock interferon
TABLE Ill. NKC ACTIVITY OF MONONUCLEAR CELLS
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in-house standard and were. expressed as the percentage inhibi-
tion of 3H-thymidine uptake (Table Il). The commercial prepa-
rations all produced higher levels of inhibition of cellular proli-
feration than the in-house standard at all dilutions tested. This is
consistent with the antiviral results. With all the preparations it
was noted that the antiproliferative activities remained elevated
on serial dilution and then dropped substantially when a specific
dilution was reached. It was thus possible to define a 'titre' as
with antibody activity. A convenient cut-off value for antiproli-
ferative activity was taken as a percentage 3H-thymidine uptake
value of greater than double that of the mock interferon. Thus,
the titre for each preparation was determined as the highest
dilution giving a percentage 3H-thymidine uptake value greater
than 30%. The titres for the Frone, Namalvin, IlBR HuIFN-a,
IlBR Iymphoblastoid interferon and the in-house standard were
found be 103, 103, lQ4, IQ4 and 102 respectively.
TABLE 11. ANTI PROLIFERATIVE ACTIVITIES OF INTERFERON
PREPARATIONS
% in hi bition of 3H-thymidine uptake by
Interferon dilution of preparation
preparations 10- 1 10-2 10-3 10-4 10-5
A 60 55 43 17 NO
HS 39 42 19 13 NO
B 46 44 44 18 NO
HS 37 37 16 13 NO
C NO 63 55 40 25
HS NO 33 14 NO NO
0 NO 64 57 40 27
HS NO 33 16 NO NO
M 15 NO NO NO NO
HS 42 NO NO NO NO
NO = not done; A = Frone; S = Namalvin; C = IISR HuIFN-Q; 0 = IISR Iymphoblasloid
interferon; HS = in-house standard: M = mock interferon. .
NKC stimulatory activity (Table Ill)
The degree to which the interferon preparations stimulated
the NKC activity of peripheral mononuclear cells was expressed
as the ratio of the lyric activity of interferon-treated cells for the
target cell (K562) relative to untreated mononuclear cells. This
index was determined at varying ratios ofeffector (mononuclear)
cells to target cells, as shown in Table Ill. Optimal results were
obtained at the effector cell: target cell ratio of20: I, although the
relative efficacies of the different interferon preparations were
the same at all of the ratios tested. It is noteworthy that the
Namalvin preparation stimuated NKC activity far more than the
other commercial preparations. It is also of interest that the
in-house standard stimulated NKCs more than the commercial
preparations other than Namalvin, even though its antiviral and
antiproliferative activities were considerably lower.
Discussion
Over the past few years there has been a dramatic upsurge in
interest in the interferons among basic scientists such as cell
biologists, biochemists and virologists, as well as among clini-
cians. The tremendous commercial pressure to find economic
ways of producing large amounts of interferon for clinical inves-
tigation has undoubtedly played a substantial role in the recent
extremely rapid developments in our understanding of the bio-
chemistry and molecular biology of the interferons. A number of
the genes have been successfully cloned in bacteria9 and yeasts,IO
and effective interferon products produced from them." The
polypeptide sequence of HuIFN-a has been elucidated 12 and
one of its genes was recently totally synthesized. 1, There is now
little doubt that soon large amounts of interferon derived from
recombinant D A techniques or chemically synthetized inter-
ferons will become available for therapeutic use.
Somewhat less dramatic have been the advances in the study
of the biology of interferons. The complex activities of these
remarkable agents have been extensively reviewed elsewhere.2-4
Their two most striking properties are their potency and the wide
range of biological activities. Interferons are the most potent
biological substances known, having demonstrable activity at
10-14 M.2 The spectrum of their activities stretches from the
inhibition of insulin-activated conversion of mouse fibroblasts to
adipocytes 14 to inhibition of myocardial contractility.15 From a
clinical point of view, however, the three most important activi-
ties ofthe interferons are their broad-spectrum antiviral activity,
their antiproliferative activity for both normal and transformed
cells and their stimulation of cytotoxic cells, especially NKC.
The best understood and most thoroughly studied of these is the
antiviral activity, and this is used to quantitate the potency of the
interferons in terms of unitage.
Least understood are their clinical activities and therapeutic
potential. It was felt that in order to obtain a greater degree of
understanding of their clinical effectiveness, parameters other
than their antiviral potency would need to be determined before
meaningful clinical trials could be planned and carried out.
Samples of four commercial preparations of therapeutic interferons
were therefore evaluated in terms of their three major activitieS in
order to characterize their potency more accurately.
The antiviral activities of two of the preparations correlated
well with the values provided by the manufacturers, but in the
other two there was a drop of approximately 50% .when the
antiviral potency was tested in our laboratory. It should be
noted, however, that one of these preparations was an HuIFN-R
and was calibrated against an HuIFN-a standard. This could
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possibly have resulted in a falsely low result. The test is, in any
event, a semiquantitative one, and a 50% variation is relatively
insignificant. At this stage of clinical trials dosages are based .on
antiviral unitage, and it would therefore seem reasonable that the
dosage provided by the manufacturers should be complemented
by in-house evaluation. This is especially of importance in the
monitoring of the dynamics of distribution and effective levels in
blood or body fluids during therapy.
The antiproliferative activity is most conveniently expressed
as a titre and correlated closely with the antiviral activity. Inter-
feron preparations purified by affinity chromatography using
monoclonal anti-interferon antibodies have displayed antiviral
and antiproliferative activities running in parallel with each
other. However, as regards Namalvin and the in-house standard,
the NKC stimulatory activities showed discrepancies when
compared with the antiviral and antiproliferative results. Both
preparations were very potent stimulators of NKCs, this being
out of proportion to their antiviral and antiproliferative activi-
ties. The in-house standard is a crude unpurified preparation,
and impurities present in this preparation and possibly also in
the Namalvin preparation may be responsible for a substantial
proportion of this significant increase in NKC stimulation.
Alternatively, it may be the case that an interferon component
with pronounced NKC stimulatory activity has been partially
lost or denatured in the purification process of the other prepara-
tions. Whatever the explanation for this discrepancy, it remains
essential that parameters other than antiviral activity should be
taken into account when clinical trials of the interferons are
planned and when the results are evaluated. This is critical not
only for the planning of dosage schedules and determination of
pharmacodynamics and stability, but also for a better under-
standing of the mechanisms of clinical action and the effective-
ness of these remarkable agents.
Addendum
A sample of recombinant leucocyte A interferon produced by the
cloning of the human leucocyte interferon (HuIFN-a) gene in
Escherichia coli and subsequent purification of the product on an
affinity column using monoclonal antibodyi6 was provided for
assay by F. Hoffmann-La Roche & Co., Basle, Switzerland. This
product was examined for antiviral activity and was found on our·
assay to yield a value of 1,6 x 106IU/m!. The stated value on the
product was 3 x 106 IU/m!.
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Nuus en Kommentaar/News and Comment
Hormone en seksualiteit by die vrou
Daar bestaan verskillende beskrywinge van die invloed van
hormone op die seksualiteit van die vrou. Hoogtepume van
seksuele aktiwiteit word aan elke fase van die menstruele siklus
gekoppel. Die afwesigheid van estrogene en progesteroon in die
postmenopouse lei tot 'n verminderdeseksuele belangstelling, 'n
verminderde kapasiteit vir orgasme en 'n lae koltllsfrekwensie.
In verskeie dubbel-blinde ondersoeke is daar gepoog om die
invloed van geslagshormone op die seksuele houding van die
vrou te bepaal. Hart (Ned Tijdschr Geneeskd 1982; 126: 1149)
skryf dar die toediening van esrrogene in vergelyking met plasebo
wel die droogheid van die vagina verminder, maar dat die
frekwensie van kOltlls, orgasme of masturbasie nie verander nie.
Daaremeen meen andere dat estrogene wel 'n versterkende
invloed op libido, seksualiteit, seksuele fanrasie en orgasme het.
In 'n studie wat in 1980 deur Dennerstein gedoen is, het hy 'n
dubbel-blinde vergelykende ondersoek by 94 vrouens gemaak
wat weens goedaardige aandoening histerektomie met bilaterale
salpingo-ooforektomie ondergaan het. In die loop van 12 maande
het hierdie vrouens afwisselend, gedurende 3 maande-periodes,
estrogeenpreparate, progesteroonprodukte of'n kombinasie van
albei of'n plasebo gekry. Die gemiddelde ouderdom van hierdie
vrouens was 46 jaar. Dit het geblyk dat estrogene wel seksuele
drange stimuleer en ook die lubrikasie van die vagina en
orgasmevermoe verbeter. Hierdie effek het afgeneem na die
toevoeging van progesteroon en ook wanneer laasgenoemde
hormoon alleen toegedien is. Estrogeen het geen invloed op die
kOlrusfrekwensie gehad nie. Die outeurs vermoed dat hierdie
frekwensie meer bepaal word deur die behoeftes van die
eggenoot terwyl die aard en frekwensie van die orgasme by die
vrou meer afuanklik van interne faktore skyn te wees.
